On Tuesday, Atossa Therapeutics Inc (NASDAQ: ATOS) opened lower -4.22% from the last session, before settling in for the closing price of $0.98. Price fluctuations for ATOS have ranged from $0.55 to $1.71 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -21.67% at the time writing. With a float of $129.13 million, this company’s outstanding shares have now reached $129.17 million.
Let’s look at the performance matrix of the company that is accounted for 15 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Atossa Therapeutics Inc (ATOS) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Atossa Therapeutics Inc is 0.03%, while institutional ownership is 26.42%. The most recent insider transaction that took place on Mar 26 ’25, was worth 7,000. In this transaction Director of this company bought 10,000 shares at a rate of $0.70, taking the stock ownership to the 10,257 shares.
Atossa Therapeutics Inc (ATOS) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -21.67% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -10.52% during the next five years compared to 36.92% growth over the previous five years of trading.
Atossa Therapeutics Inc (NASDAQ: ATOS) Trading Performance Indicators
Check out the current performance indicators for Atossa Therapeutics Inc (ATOS). In the past quarter, the stock posted a quick ratio of 12.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.21, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.27 in one year’s time.
Technical Analysis of Atossa Therapeutics Inc (ATOS)
Atossa Therapeutics Inc (NASDAQ: ATOS) saw its 5-day average volume 1.06 million, a positive change from its year-to-date volume of 0.68 million. As of the previous 9 days, the stock’s Stochastic %D was 63.89%. Additionally, its Average True Range was 0.07.
During the past 100 days, Atossa Therapeutics Inc’s (ATOS) raw stochastic average was set at 73.85%, which indicates a significant increase from 55.90% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 83.47% in the past 14 days, which was higher than the 70.99% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7476, while its 200-day Moving Average is $1.0718. Nevertheless, the first resistance level for the watch stands at $0.9781 in the near term. At $1.0140, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.0381. If the price goes on to break the first support level at $0.9181, it is likely to go to the next support level at $0.8940. The third support level lies at $0.8581 if the price breaches the second support level.
Atossa Therapeutics Inc (NASDAQ: ATOS) Key Stats
There are currently 129,170K shares outstanding in the company with a market cap of 121.69 million. Presently, the company’s annual sales total 0 K according to its annual income of -25,500 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -6,720 K.
